慢性心力衰竭应用卡维地洛和比索洛尔治疗的疗效比较

目的 探讨卡维地洛和比索洛尔治疗慢性心力衰竭患者的临床效果.方法 收集本院2014年3月至2015年3月收治的80例慢性心力衰竭患者,随机分为两组.卡维地洛组给予卡维地洛治疗,比索洛尔组给予比索洛尔治疗,比较两组心功能治疗效果、相关临床指标与不良反应.结果 卡维地洛组心功能治疗总有效率(95.0％)明显高于比索洛尔组(77.5％),差异有统计学意义(P＜0.05);卡维地洛组HR(70.67±7.27)次/min,SBP(104.25±10.58) mmHg,DBP(70.43±7.06) mmHg,LVEDD(57.01±5.74) mm,LVESD(42.99±4.16) mm,MVO2(7 215±876)m与BNP(536.15±79.15) ng/L与NT-proBNP水平(462.10±50.17)ng/L,均显著低于比索洛尔组(76.45±7.63)次/min,(116.73±16.18)mmHg,(75.89±7.21) mmHg,(61.50±5.99) mm]、(47.42±4.41)mm,(8 159±977),(816.08±94.35)ng/L,(743.21±58.94)ng/L],6MWT(421.54±37.76)m,LVEF水平(50.63±5.74)％]显著高于比索洛尔组(369.84±29.16)m、(42.56±4.76)％],差异有统计学意义(P＜0.01);两组总体不良反应发生率差异无统计学意义(5％ vs.10％,P＞ 0.05).结论 卡维地洛治疗慢性心力衰竭患者的临床效果显著优于比索洛尔,且安全性较高,具有借鉴性.

Carvedilol versus bisoprolol in treatment of chronic heart failure

Objective To investigate the clinical efficacy of carvedilol versus bisoprolol for patients with chronic heart failure.Methods 80 patients with chronic heart failure admitted into our hospital from March,2013 to March,2015 were collected and randomly divided into two groups.Group A was treated with carvedilol and group B bisoprolol.The clinical efficacy of cardiac function,the related clinical indicators,and adverse reactions were compared between these two groups.Results The total efficacy of cardiac function was 95.0％ in group A and 77.5％ in group B,with a statistical difference (P＜0.05).The HR,SBP,DBP,LVEDD,LVESD,MVO2,BNP level,and NT-proBNP level were (70.67±7.27) beat/min,(104.25±10.58) mmHg,(70.43±7.06)mmHg,(57.01±5.74) mm,(42.99±4.16) mm,(7 215±876),(536.15±79.15) ng/L,and (462.10±50.17) ng/L in group A,which were significantly lower than those in group B (76.45±7.63) beat/min,(116.73±16.18) mmHg,(75.89±7.21) mmHg,(61.50±5.99) mm,(47.42±4.41) mm,(8 159±977),(816.08±94.35) ng/L,(743.21±58.94)ng/L;the 6MWT and LVEF were higher in group A than in group B (421.54±37.76) m vs.(369.84±29.16) m and (50.63±5.74)％ vsv (42.56±4.76)％];with statistical differences.There was no statistical difference in the incidence of adverse reactions between these two groups (5％ vs.10％,P＞0.05).Conclusions Carvedilol for patients with chronic heart failure is significantly more effective and safer than bisoprolol,so it is of reference in clinical practice.